SCHEMBL2693252

SCHEMBL2693252

Cc1cc(Nc2cc(N(C)c3cncc(F)c3)c(C(N)=O)cn2)ccc1C(=O)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 3/20 0.44
▸ TYK2 P29597 3/20 0.44
▸ JAK2 O60674 2/20 0.44
▸ MAPK9 P45984 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ CDK2 P24941 3/20 0.41
▸ NNMT P40261 1/20 0.37
▸ EIF2S1 P05198 1/20 0.37
▸ EIF2AK3 Q9NZJ5 1/20 0.37
▸ CSF1R P07333 4/20 0.37
▸ KCNH2 Q12809 2/20 0.35
▸ JAK3 P52333 3/20 0.35
▸ IRAK4 Q9NWZ3 2/20 0.35
▸ PTK2 Q05397 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695042 0.89 MAPK9 (0.46) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2694914 0.89 MAPK9 (0.52) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2696692 0.87 JAK2 (0.41) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2697897 0.84 SIRT2 (0.43) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2695013 0.84 LMNA (0.47) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2693081 0.83 CSF1R (0.40) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2697557 0.83 SYK (0.46) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2694449 0.83 CSF1R (0.45) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2697293 0.82 CSF1R (0.39) JAK1TYK2JAK2MAPK9MAPK10
SCHEMBL2693472 0.82 CNR2 (0.46) JAK1TYK2JAK2MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 — — US claimed
EP-2635557-A2 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP claimed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO claimed
EP-2975027-A1 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2016-01-20 — — EP disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 — — US disclosed
EP-2635557-A2 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP disclosed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK JAK1 2/4885TYK2 7/4885JAK2 1/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK JAK1 2/4885TYK2 7/4885JAK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback